Menlo Park, United States
MedaSystems, founded in 2021, is an innovative player in the Biopharma and Pharmaceutical industries. Their slogan, "The leading AI-driven SaaS platform that manages Expanded Access for top tier pharmaceutical companies worldwide," aptly captures their mission.
The company offers a cloud-based software platform designed to optimize the management of requests for investigational medicines. The platform is instrumental in automating workflows, facilitating collaboration between manufacturers and Health Care Providers, and ensuring compliance with regulatory standards—all while capturing essential real-world data. MedaSystems' solution supports expanded access programs, post-trial access, and investigator-initiated studies, setting a new standard in the industry.
Headquartered in the United States, MedaSystems recently secured seed round funding, with investment from the Debiopharm Innovation Fund on 09 January 2024. This investment underscores their potential to impact the pharmaceutical landscape significantly.
